Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (128)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
  7. Research Letter (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (287)
  2. Breast Medicine Service (287)
  3. Department of Medicine (287)
  4. GSK Faculty (287)
  5. Human Oncology and Pathogenesis Program (287)
  6. Solid Tumor Oncology Division (287)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (58)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (17)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
    Meeting Abstract

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling
    Journal Article

    She, Q. B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N.
    PLoS ONE (2008)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
    Journal Article

    Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C. L.; Sellers, W.; Rosen, N.; Solit, D. B.
    Cancer Research (2008)

    Fulltext@MSK | Save
  • SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers
    Journal Article

    Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save